Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


Celecoxib better than diclofenac sodium for knee osteoarthritis

08 Sep 2020

Patients with knee osteoarthritis may experience better pain relief with celecoxib than with diclofenac sodium, in addition to having lower levels of inflammatory markers and complication risk, a study has found.

Researchers performed a systematic review and meta-analysis of 12 trials comparing the efficacy of the two painkillers in terms of knee pain, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), visual analogue scale (VAS) score, and complication rate.

There were 2,350 individuals included in the studies, with 1,189 in the celecoxib group and 1,161 in the diclofenac sodium group. Pooled data showed that treatment efficacy (rate graded as follows: clinically controlled, significantly improved, improved, or ineffective) was substantially greater with celecoxib (odds ratio [OR], 3.40, 95 percent confidence interval [CI], 2.17–5.32; p≤0.001), with good statistical homogeneity among the studies (I2, 17.3 percent).

In terms of pain (assessed using the VAS score), celecoxib likewise proved more effective than diclofenac sodium (standardized mean difference [SMD], −1.44, 95 percent CI, −2.27 to −0.60; p≤0.001), with high heterogeneity.

Celecoxib also showed superiority to the other drug with respect to reducing CRP (SMD, −9.73, 95 percent CI, −15.75 to −3.72; p=0.002) and ESR (SMD, 5.56, 95 percent CI, 2.05–9.06; p=0.002), and the incidence of complications (OR, 0.34, 95 percent CI, 0.20–0.59; p≤0.001).

The findings suggest that celecoxib may favourably impact treatment of knee osteoarthritis by reducing pain, inflammatory markers and incidence of complications. Nevertheless, well-designed and high-quality trials are still needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.